Erasca
NASDAQ · ERAS·San Diego, CA·Small-cap·Phase 1
Clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers. Lead asset ERAS-0015 is a pan-RAS molecular glue in Phase 1 (AURORAS-1) for RAS-mutant solid tumors.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Erasca Corporate Presentation April 2026 | Corporate overview | April 27, 2026 | 32 |